Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtre
1.
J. bras. nefrol ; 38(2): 255-259, tab, graf
Article Dans Portugais | LILACS | ID: lil-787883

Résumé

Resumo A gencitabina é um fármaco utilizado no tratamento de vários tipos de neoplasias malignas. Há poucas descrições de associação entre a droga e a síndrome hemolítico-urêmica (SHU), apesar de os pacientes em questão terem ido a óbito em pelo menos 50% dos casos. O presente artigo relata o caso de uma paciente com 25 anos de idade em remissão diagnosticada com colangiocarcinoma que apresentou anemia hemolítica microangiopática acompanhada de insuficiência renal aguda anúrica após cinco ciclos de quimioterapia com gencitabina; as manifestações eram condizentes com SHU causada pelos efeitos colaterais do medicamento. A administração de gencitabina foi interrompida, e a paciente foi tratada com hemodiálise, transfusões de sangue, trocas de plasma, corticosteroides, doxiciclina e rituximabe. Foi atingido um desfecho favorável; mais especificamente, a hemólise foi controlada e a função renal foi plenamente restabelecida.


Abstract Gemcitabine is a medication used to treat various types of malignant neoplasms. Its association with hemolytic uremic syndrome (HUS) has been described in few cases, although these cases have resulted in mortality rates of at least 50%. We report on the case of a 25-year-old patient with cholangiocarcinoma in remission who developed microangiopathic hemolytic anemia with acute anuric renal failure after receiving 5 cycles of gemcitabine chemotherapy; this condition was consistent with HUS caused by the side effects of this drug. The administration of gemcitabine was stopped, and hemodialysis, blood transfusions, plasma exchanges, steroids, doxycycline, and rituximab were used to treat the patient. A favorable outcome was achieved; in particular, hemolysis was controlled, and renal function was completely recovered.


Sujets)
Humains , Femelle , Adulte , Désoxycytidine/analogues et dérivés , Syndrome hémolytique et urémique/induit chimiquement , Antimétabolites antinéoplasiques/effets indésirables , Tumeurs des canaux biliaires/traitement médicamenteux , Cholangiocarcinome/traitement médicamenteux , Désoxycytidine/effets indésirables , Désoxycytidine/usage thérapeutique , Antimétabolites antinéoplasiques/usage thérapeutique
2.
Gut and Liver ; : 109-112, 2014.
Article Dans Anglais | WPRIM | ID: wpr-36645

Résumé

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Antimétabolites antinéoplasiques/effets indésirables , Désoxycytidine/effets indésirables , Syndrome hémolytique et urémique/induit chimiquement , Tumeurs du pancréas/traitement médicamenteux , Résultat thérapeutique
3.
Rev. méd. Chile ; 141(6): 797-802, jun. 2013. ilus
Article Dans Espagnol | LILACS | ID: lil-687212

Résumé

Gemcitabine is a widely used drug in the treatment of advanced pancreatic cancer and other malignancies. It is generally well tolerated and exceptionally its use has been associated with hemolytic-uremic syndrome, causing acute kidney injury, hipertension, chronic renal failure requiring dialysis, and death. We report a 60-year-old man with pancreatic carcinoma and regional lymph node invasion, whom after four months of therapy with gemcitabine and after dose number 11, suddenly developed an acute nephritic syndrome with moderate renal impairment, associated with severe anemia (hemoglobin 6.0 g/dL) and thrombocytopenia (20,000 mm³). Renal biopsy showed the classic findings of thrombotic micro angiopathy Gemcitabine was discontinued and renal function and hematological parameters gradually improved.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Antimétabolites antinéoplasiques/effets indésirables , Désoxycytidine/analogues et dérivés , Syndrome hémolytique et urémique/induit chimiquement , Antimétabolites antinéoplasiques/usage thérapeutique , Désoxycytidine/effets indésirables , Désoxycytidine/usage thérapeutique , Tumeurs du pancréas/traitement médicamenteux
4.
J Postgrad Med ; 2002 Jul-Sep; 48(3): 197-8
Article Dans Anglais | IMSEAR | ID: sea-117284

Résumé

Thrombotic microangiopathy, which broadly includes thrombotic thrombocytopaenic purpura (TTP) and haemolytic uraemic syndrome (HUS), is a multisystemic disorder that is characterised by thrombocytopaenia, microangiopathic haemolytic anemia and ischaemic manifestations, resulting from platelet agglutination in the arterial microvasculature. Acral necrosis (distal necrosis of fingers and toes) occurs usually as a sequel to severe Raynaud's phenomenon, a vasculospastic disorder frequently related to endothelial cell dysfunction. We report a case of quinine induced TTP-HUS and acral necrosis, two distinct clinical abnormalities which have not yet been reported together in association with quinine. Both of these conditions in this case resolved promptly to treatment with corticosteroids.


Sujets)
Hormones corticosurrénaliennes/administration et posologie , Sujet âgé , Ponction-biopsie à l'aiguille , Études de suivi , Syndrome hémolytique et urémique/induit chimiquement , Humains , Immunohistochimie , Mâle , Nécrose , Purpura thrombotique thrombocytopénique/induit chimiquement , Quinine/administration et posologie , Appréciation des risques , Orteils/anatomopathologie , Résultat thérapeutique
5.
Acta oncol. bras ; 6(2): 90-4, maio-ago. 1986. ilus
Article Dans Portugais | LILACS | ID: lil-37692

Résumé

A mitomicina C é um antibiótico alquilante freqüentemente usado nos esquemas poliquimioterápicos para o tratamento dos tumores do trato gastrintestinal e de mama. Além dos efeitos tóxicos habituais dos agentes antineoplásicos, a mitomicina C pode induzir à síndrome hemolítico-urêmica com graus variáveis de insuficiência renal. Descreve-se um paciente portador de câncer gástrico que evolui a partir do quarto ciclo do esquema FAM com anemia hemolítica, insuficiência renal, plaquetopenia e hipertensäo arterial. Instituída a terapêutica com plasmaferese e transfusäo de plasma fresco, o paciente evolui satisfatoriamente. Discute-se o diagnóstico e a terapêutica dessa síndrome


Sujets)
Adulte d'âge moyen , Humains , Mâle , Syndrome hémolytique et urémique/induit chimiquement , Mitomycines/effets indésirables , Mitomycines/usage thérapeutique , Tumeurs de l'estomac/traitement médicamenteux
SÉLECTION CITATIONS
Détails de la recherche